Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
1.
J Immunol ; 206(4): 686-699, 2021 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-33419770

RESUMEN

East Coast fever (ECF), caused by Theileria parva, is the most important tick-borne disease of cattle in sub-Saharan Africa. Practical disadvantages associated with the currently used live-parasite vaccine could be overcome by subunit vaccines. An 80-aa polypeptide derived from the C-terminal portion of p67, a sporozoite surface Ag and target of neutralizing Abs, was the focus of the efforts on subunit vaccines against ECF and subjected to several vaccine trials with very promising results. However, the vaccination regimen was far from optimized, involving three inoculations of 450 µg of soluble p67C (s-p67C) Ag formulated in the Seppic adjuvant Montanide ISA 206 VG. Hence, an improved formulation of this polypeptide Ag is needed. In this study, we report on two nanotechnologies that enhance the bovine immune responses to p67C. Individually, HBcAg-p67C (chimeric hepatitis B core Ag virus-like particles displaying p67C) and silica vesicle (SV)-p67C (s-p67C adsorbed to SV-140-C18, octadecyl-modified SVs) adjuvanted with ISA 206 VG primed strong Ab and T cell responses to p67C in cattle, respectively. Coimmunization of cattle (Bos taurus) with HBcAg-p67C and SV-p67C resulted in stimulation of both high Ab titers and CD4 T cell response to p67C, leading to the highest subunit vaccine efficacy we have achieved to date with the p67C immunogen. These results offer the much-needed research depth on the innovative platforms for developing effective novel protein-based bovine vaccines to further the advancement.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Nanotecnología/métodos , Vacunas Antiprotozoos/inmunología , Theileria parva/fisiología , Theileriosis/inmunología , Enfermedades por Picaduras de Garrapatas/inmunología , Animales , Anticuerpos Antiprotozoarios/sangre , Bovinos , Virus de la Hepatitis B/química , Virus de la Hepatitis B/genética , Ratones , Aceite Mineral/administración & dosificación , Nanopartículas/química , Proteínas Protozoarias/genética , Vacunas Antiprotozoos/genética , Células RAW 264.7 , Dióxido de Silicio/química , Garrapatas , Vacunación , Vacunas de Subunidad , Proteínas del Núcleo Viral/química , Proteínas del Núcleo Viral/genética
2.
Viruses ; 13(1)2020 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-33396288

RESUMEN

Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody-based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane. Using this assay, we screened nearly 3000 small molecules and identified several molecules with the desired inhibitory properties. In secondary assays, one identified compound, sangivamycin, inhibited not only Ebola viral infectivity but also that of other viruses. This finding indicates that it is possible for this new VP40-based screening method to identify highly potent MCMs against Ebola virus and its relatives.


Asunto(s)
Antivirales/farmacología , Ebolavirus/efectos de los fármacos , Nucleoproteínas/antagonistas & inhibidores , Proteínas del Núcleo Viral/antagonistas & inhibidores , Animales , Antivirales/química , Antivirales/uso terapéutico , Chlorocebus aethiops , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Ebolavirus/genética , Regulación Viral de la Expresión Génica/efectos de los fármacos , Células HEK293 , Fiebre Hemorrágica Ebola/tratamiento farmacológico , Fiebre Hemorrágica Ebola/virología , Humanos , Contramedidas Médicas , Estructura Molecular , Nucleoproteínas/química , Nucleósidos de Pirimidina/farmacología , Células Vero , Proteínas del Núcleo Viral/química , Liberación del Virus/efectos de los fármacos
3.
Nat Commun ; 10(1): 2184, 2019 05 16.
Artículo en Inglés | MEDLINE | ID: mdl-31097716

RESUMEN

Chronic hepatitis B virus (HBV) infection can cause cirrhosis and hepatocellular carcinoma and is therefore a serious public health problem. Infected patients are currently treated with nucleoside/nucleotide analogs and interferon α, but this approach is not curative. Here, we screen 978 FDA-approved compounds for their ability to inhibit HBV replication in HBV-expressing HepG2.2.15 cells. We find that ciclopirox, a synthetic antifungal agent, strongly inhibits HBV replication in cells and in mice by blocking HBV capsid assembly. The crystal structure of the HBV core protein and ciclopirox complex reveals a unique binding mode at dimer-dimer interfaces. Ciclopirox synergizes with nucleoside/nucleotide analogs to prevent HBV replication in cells and in a humanized liver mouse model. Therefore, orally-administered ciclopirox may provide a novel opportunity to combat chronic HBV infection by blocking HBV capsid assembly.


Asunto(s)
Antivirales/farmacología , Ciclopirox/farmacología , Virus de la Hepatitis B/fisiología , Hepatitis B Crónica/tratamiento farmacológico , Ensamble de Virus/efectos de los fármacos , Animales , Antivirales/uso terapéutico , Cápside/efectos de los fármacos , Cápside/metabolismo , Ciclopirox/química , Ciclopirox/uso terapéutico , Cristalografía por Rayos X , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Células Hep G2 , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B Crónica/patología , Hepatitis B Crónica/virología , Hepatocitos/trasplante , Hepatocitos/virología , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones SCID , ARN Viral/metabolismo , Quimera por Trasplante , Resultado del Tratamiento , Proteínas del Núcleo Viral/química , Proteínas del Núcleo Viral/metabolismo , Replicación Viral/efectos de los fármacos
4.
Analyst ; 144(9): 2881-2890, 2019 May 07.
Artículo en Inglés | MEDLINE | ID: mdl-30788466

RESUMEN

Although natural herbs have been a rich source of compounds for drug discovery, identification of bioactive components from natural herbs suffers from low efficiency and prohibitive cost of the conventional bioassay-based screening platforms. Here we develop a new strategy that integrates virtual screening, affinity mass spectrometry (MS) and targeted metabolomics for efficient discovery of herb-derived ligands towards a specific protein target site. Herb-based virtual screening conveniently selects herbs of potential bioactivity whereas affinity MS combined with targeted metabolomics readily screens candidate compounds in a high-throughput manner. This new integrated approach was benchmarked on screening chemical ligands that target the hydrophobic pocket of the nucleoprotein (NP) of Ebola viruses for which no small molecule ligands have been reported. Seven compounds identified by this approach from the crude extracts of three natural herbs were all validated to bind to the NP target in pure ligand binding assays. Among them, three compounds isolated from Piper nigrum (HJ-1, HJ-4 and HJ-6) strongly promoted the formation of large NP oligomers and reduced the protein thermal stability. In addition, cooperative binding between these chemical ligands and an endogenous peptide ligand was observed, and molecular docking was employed to propose a possible mechanism. Taken together, we established a platform integrating in silico and experimental screening approaches for efficient discovery of herb-derived bioactive ligands especially towards non-enzyme protein targets.


Asunto(s)
Productos Biológicos/metabolismo , Espectrometría de Masas/métodos , Metabolómica/métodos , Nucleoproteínas/metabolismo , Extractos Vegetales/metabolismo , Proteínas del Núcleo Viral/metabolismo , Sitios de Unión , Productos Biológicos/química , Productos Biológicos/aislamiento & purificación , Descubrimiento de Drogas/métodos , Ebolavirus/química , Ligandos , Simulación del Acoplamiento Molecular , Proteínas de la Nucleocápside , Nucleoproteínas/química , Ophiopogon/química , Piper nigrum/química , Componentes Aéreos de las Plantas/química , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Unión Proteica , Salvia miltiorrhiza/química , Semillas/química , Proteínas del Núcleo Viral/química
5.
BMC Complement Altern Med ; 16(1): 519, 2016 Dec 16.
Artículo en Inglés | MEDLINE | ID: mdl-27986088

RESUMEN

BACKGROUND: Different strains of influenza virus are affecting a large number of people worldwide. Many synthetic antiviral medicines are available for influenza virus in the market. But still there is a need for the development of universal drugs against these strains of influenza virus. METHODS: For this purpose conserved residues within the influenza virus nucleoprotein have been retrieved. The drugs, previously known to have antiviral properties, were screened to identify the best candidate universal drug against Influenza virus strains. Compounds from leaf extracts of neem, were also screened to identify the natural drugs without side effects. RESULT: Molecular docking identified three potential compounds (Nimbaflavone, Rutin, and Hyperoside) having perfect binding with reported conserved residues (ASP302, SER50) of influenza virus nucleoprotein that is involved in the binding of drugs. Further analysis showed Hyperoside as a universal drug against various influenza strains. Some chemical drugs were also evaluated through screening against nucleoprotein. The results showed six drugs (OMS, CBX, LGH, Naproxen, BMS-883559, and BMS-885838) which were interacting with same conserved residues (ASP302, TYR52, SER50, GLY288, SER376, and ARG99) as were found in the case of neem phytochemicals. Hyperoside from neem leaf extract along with drugs LGH, Naproxen, BMS-885838, and BMS-883559 showed best interactions with conserved residues of nucleoprotein. CONCLUSION: The compound Hyperoside from neem leaf extract along with drugs LGH, Naproxen, BMS-885838, and BMS-883559 showed best interactions with conserved residues of nucleoprotein. So these compounds have been identified for their potential against influenza strains to be utilized as a universal drug.


Asunto(s)
Antivirales/farmacología , Azadirachta/química , Virus de la Influenza A/efectos de los fármacos , Gripe Humana/virología , Extractos Vegetales/farmacología , Proteínas de Unión al ARN/antagonistas & inhibidores , Proteínas del Núcleo Viral/antagonistas & inhibidores , Secuencia de Aminoácidos , Antivirales/química , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Virus de la Influenza A/química , Virus de la Influenza A/genética , Virus de la Influenza A/metabolismo , Simulación del Acoplamiento Molecular , Datos de Secuencia Molecular , Proteínas de la Nucleocápside , Extractos Vegetales/química , Proteínas de Unión al ARN/química , Proteínas de Unión al ARN/genética , Proteínas de Unión al ARN/metabolismo , Alineación de Secuencia , Proteínas del Núcleo Viral/química , Proteínas del Núcleo Viral/genética , Proteínas del Núcleo Viral/metabolismo
6.
Molecules ; 20(3): 5152-64, 2015 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-25808156

RESUMEN

Structure-based virtual screening for selecting potential drug candidates is usually challenged by how numerous false positives in a molecule library are excluded when receptor plasticity is considered. In this study, based on the binding energy landscape theory, a hypothesis that a true inhibitor can bind to different conformations of the binding site favorably was put forth, and related strategies to defeat this challenge were devised; reducing false positives when receptor plasticity is considered. The receptor in the study is the influenza A nucleoprotein, whose oligomerization is a requirement for RNA binding. The structural flexibility of influenza A nucleoprotein was explored by molecular dynamics simulations. The resultant distinctive structures and the crystal structure were used as receptor models in docking exercises in which two binding sites, the tail-loop binding pocket and the RNA binding site, were targeted with the Otava PrimScreen1 diversity-molecule library using the GOLD software. The intersection ligands that were listed in the top-ranked molecules from all receptor models were selected. Such selection strategy successfully distinguished high-affinity and low-affinity control molecules added to the molecule library. This work provides an applicable approach for reducing false positives and selecting true ligands from molecule libraries.


Asunto(s)
Modelos Químicos , Modelos Moleculares , Proteínas de Unión al ARN/química , Proteínas de Unión al ARN/metabolismo , Bibliotecas de Moléculas Pequeñas/metabolismo , Proteínas del Núcleo Viral/química , Proteínas del Núcleo Viral/metabolismo , Sitios de Unión/efectos de los fármacos , Simulación por Computador , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos , Reacciones Falso Positivas , Simulación del Acoplamiento Molecular , Proteínas de la Nucleocápside , Conformación Proteica , Programas Informáticos , Relación Estructura-Actividad
7.
PLoS One ; 9(5): e97579, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24827459

RESUMEN

Despite an existing effective vaccine, hepatitis B virus (HBV) remains a major public health concern. There are effective suppressive therapies for HBV, but they remain expensive and inaccessible to many, and not all patients respond well. Furthermore, HBV can persist as genomic covalently closed circular DNA (cccDNA) that remains in hepatocytes even during otherwise effective therapy and facilitates rebound in patients after treatment has stopped. Therefore, the need for an effective treatment that targets active and persistent HBV infections remains. As a novel approach to treat HBV, we have targeted the HBV genome for disruption to prevent viral reactivation and replication. We generated 3 zinc finger nucleases (ZFNs) that target sequences within the HBV polymerase, core and X genes. Upon the formation of ZFN-induced DNA double strand breaks (DSB), imprecise repair by non-homologous end joining leads to mutations that inactivate HBV genes. We delivered HBV-specific ZFNs using self-complementary adeno-associated virus (scAAV) vectors and tested their anti-HBV activity in HepAD38 cells. HBV-ZFNs efficiently disrupted HBV target sites by inducing site-specific mutations. Cytotoxicity was seen with one of the ZFNs. scAAV-mediated delivery of a ZFN targeting HBV polymerase resulted in complete inhibition of HBV DNA replication and production of infectious HBV virions in HepAD38 cells. This effect was sustained for at least 2 weeks following only a single treatment. Furthermore, high specificity was observed for all ZFNs, as negligible off-target cleavage was seen via high-throughput sequencing of 7 closely matched potential off-target sites. These results show that HBV-targeted ZFNs can efficiently inhibit active HBV replication and suppress the cellular template for HBV persistence, making them promising candidates for eradication therapy.


Asunto(s)
Antivirales/metabolismo , Endonucleasas/genética , Productos del Gen pol/genética , Marcación de Gen , Virus de la Hepatitis B/genética , Transactivadores/genética , Proteínas del Núcleo Viral/genética , Antivirales/química , Secuencia de Bases , Línea Celular Tumoral , Roturas del ADN de Doble Cadena , Reparación del ADN por Unión de Extremidades , ADN Viral/genética , Dependovirus/genética , Endonucleasas/química , Endonucleasas/metabolismo , Productos del Gen pol/antagonistas & inhibidores , Productos del Gen pol/química , Vectores Genéticos , Células HEK293 , Virus de la Hepatitis B/química , Hepatocitos/virología , Humanos , Datos de Secuencia Molecular , Ingeniería de Proteínas , Transactivadores/antagonistas & inhibidores , Transactivadores/química , Proteínas del Núcleo Viral/antagonistas & inhibidores , Proteínas del Núcleo Viral/química , Proteínas Reguladoras y Accesorias Virales , Replicación Viral/genética , Dedos de Zinc/genética
8.
Proteomics ; 13(23-24): 3537-47, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24123778

RESUMEN

Inactivation of intact influenza viruses using formaldehyde or ß-propiolactone (BPL) is essential for vaccine production and safety. The extent of chemical modifications of such reagents on viral proteins needs to be extensively investigated to better control the reactions and quality of vaccines. We have evaluated the effect of BPL inactivation on two candidate re-assortant vaccines (NIBRG-121xp and NYMC-X181A) derived from A/California/07/2009 pandemic influenza viruses using high-resolution FT-ICR MS-based proteomic approaches. We report here an ultra performance LC MS/MS method for determining full-length protein sequences of hemagglutinin and neuraminidase through protein delipidation, various enzymatic digestions, and subsequent mass spectrometric analyses of the proteolytic peptides. We also demonstrate the ability to reliably identify hundreds of unique sites modified by propiolactone on the surface of glycoprotein antigens. The location of these modifications correlated with changes to protein folding, conformation, and stability, but demonstrated no effect on protein disulfide linkages. In some cases, these modifications resulted in suppression of protein function, an effect that correlated with the degree of change of the modified amino acids' side chain length and polarity.


Asunto(s)
Vacunas contra la Influenza/química , Neuraminidasa/química , Propiolactona/química , Proteínas de Unión al ARN/química , Proteínas del Núcleo Viral/química , Proteínas Virales/química , Inactivación de Virus , Secuencia de Aminoácidos , Antígenos Virales/química , Cisteína/química , Hemaglutininas/química , Proteínas de la Nucleocápside , Polisacáridos/química , Espectrometría de Masas en Tándem
9.
Biochem Biophys Res Commun ; 394(3): 721-7, 2010 Apr 09.
Artículo en Inglés | MEDLINE | ID: mdl-20230782

RESUMEN

The nucleoprotein (NP) of the influenza virus is expressed in the early stage of infection and plays important roles in numerous steps of viral replication. NP is relatively well conserved compared with viral surface spike proteins. This study experimentally demonstrates that NP is a novel target for the development of new antiviral drugs against the influenza virus. First, artificial analogs of mycalamide A in a chemical array bound specifically with high affinity to NP. Second, the compounds inhibited multiplication of the influenza virus. Furthermore, surface plasmon resonance imaging experiments demonstrated that the binding activity of each compound to NP correlated with its antiviral activity. Finally, it was shown that these compounds bound NP within the N-terminal 110-amino acid region but their binding abilities were dramatically reduced when the N-terminal 13-amino acid tail was deleted, suggesting that the compounds might bind to this region, which mediates the nuclear transport of NP and its binding to viral RNA. These data suggest that compound binding to the N-terminal 13-amino acid tail region may inhibit viral replication by inhibiting the functions of NP. Collectively, these results strongly suggest that chemical arrays are convenient tools for the screening of viral product inhibitors.


Asunto(s)
Antivirales/aislamiento & purificación , Descubrimiento de Drogas/métodos , Piranos/química , Proteínas de Unión al ARN/antagonistas & inhibidores , Proteínas del Núcleo Viral/antagonistas & inhibidores , Secuencia de Aminoácidos , Animales , Antivirales/química , Antivirales/farmacología , Células COS , Chlorocebus aethiops , Evaluación Preclínica de Medicamentos/métodos , Humanos , Virus de la Influenza A , Proteínas de la Nucleocápside , Procesos Fotoquímicos , Piranos/farmacología , Proteínas de Unión al ARN/química , Proteínas del Núcleo Viral/química , Replicación Viral/efectos de los fármacos
10.
Assay Drug Dev Technol ; 8(1): 96-105, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20035614

RESUMEN

Binding of hepatitis C virus (HCV) RNA to core, the capsid protein, results in the formation of the nucleocapsid, the first step in the assembly of the viral particle. A novel assay was developed to discover small molecule inhibitors of core dimerization. This assay is based on time-resolved fluorescence resonance energy transfer (TR-FRET) between anti-tag antibodies labeled with either europium cryptate (Eu) or allophycocyanin (XL-665). The N-terminal 106-residue portion of core protein (core106) was tagged with either glutathione-S-transferase (GST) or a Flag peptide. Tag-free core106 was selected as the reference inhibitor. The assay was used to screen the library of pharmacologically active compounds (LOPAC) consisting of 1,280 compounds and a 2,240-compound library from the Center for Chemical Methodology and Library Development at Boston University (CMLD-BU). Ten of the 28 hits from the primary TR-FRET run were confirmed in a secondary amplified luminescent proximity homogeneous assay (ALPHA screen). One hit was further characterized by dose-response analysis yielding an IC(50) of 9.3 microM. This 513 Da compound was shown to inhibit HCV production in cultured hepatoma cells.


Asunto(s)
Antivirales/farmacología , Evaluación Preclínica de Medicamentos/métodos , Transferencia Resonante de Energía de Fluorescencia/métodos , Hepacivirus/efectos de los fármacos , Multimerización de Proteína/efectos de los fármacos , Proteínas del Núcleo Viral/antagonistas & inhibidores , Ensayo de Inmunoadsorción Enzimática , Proteínas del Núcleo Viral/química
11.
Biol Pharm Bull ; 29(9): 1810-4, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16946490

RESUMEN

The inhibitory effect of suramin on the phosphorylation of GST-HBV core fusion protein (GST-Hcore) and two GST-Hcore fusion polypeptides (Hcore157B and Hcore164B) by two alpha-type cAMP-dependent protein kinases (PKAIalpha and PKAIIalpha) was biochemically investigated in vitro. It was found that (i) this phosphorylation was inhibited by suramin at a low concentration (IC(50)=approx. 10 nM); (ii) a relative high dose of suramin was required to inhibit an autophosphorylation of PKAIIalpha (IC(50)=approx. 0.7 muM) and the PKAIIalpha-mediated phosphorylation of histone H2B (IC(50)=approx. 0.4 muM); (iii) the PKAIIalpha-mediated phosphorylation of Hcore157B was more sensitive to suramin than the phosphorylation of Hcore157B by Ca(2+)-dependent protein kinase (PKC); and (iv) suramin had a high binding affinity for Hcore157B, but not for histone H2B in vitro. These results suggest that suramin selectively inhibits the PKA-mediated phosphorylation of HBV-CP through the direct binding in vitro of suramin to the Arg-rich C-terminal region (containing three potential phosphorylation sites for PKA) on HBV-CP.


Asunto(s)
Proteínas Quinasas Dependientes de AMP Cíclico/antagonistas & inhibidores , Virus de la Hepatitis B/efectos de los fármacos , Suramina/farmacología , Proteínas del Núcleo Viral/metabolismo , Proteínas Quinasas Dependientes de AMP Cíclico/fisiología , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Fosforilación , Proteínas Recombinantes de Fusión/metabolismo , Canal Liberador de Calcio Receptor de Rianodina/metabolismo , Suramina/metabolismo , Proteínas del Núcleo Viral/química
12.
Biochimie ; 88(7): 887-96, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16626853

RESUMEN

Potyvirus RNA contains at the 5' end a covalently linked virus-encoded protein VPg, which is required for virus infectivity. This role has been attributed to VPg interaction with the eukaryotic translation initiation factor eIF4E, a cap-binding protein. We characterized the dissociation constants for the interaction of the potato virus Y VPg with different plant eIF4Es and its isoforms and mapped the eIF(iso)4E attachment region on VPg. VPg/eIF4E interaction results in the inhibition of cell-free protein synthesis, and we show that it stems from the liberation of the cap moiety from the complex with eIF4E. Since VPg does not attach the cap, it appears that VPg induces changes in the eIF4E structure, diminishing its affinity to the cap. We show here that the initiation complex scaffold protein eIF(iso)4G increases VPg interaction with eIF(iso)4E. These data together suggest similar cap and VPg interactions with eIF4E and characterize VPg as a novel eIF4E-binding protein, which inhibits host protein synthesis at a very early stage of the initiation complex formation through the inhibition of cap attachment to the initiation factor eIF4E.


Asunto(s)
Factor 4E Eucariótico de Iniciación/metabolismo , Potyvirus/metabolismo , Proteínas del Núcleo Viral/metabolismo , Secuencia de Aminoácidos , Sitios de Unión , Cromatografía de Afinidad , Quimotripsina/metabolismo , Electroforesis en Gel de Poliacrilamida , Ensayo de Inmunoadsorción Enzimática , Factor 4E Eucariótico de Iniciación/química , Guanosina Trifosfato/metabolismo , Datos de Secuencia Molecular , Potyvirus/patogenicidad , Unión Proteica , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Estructura Terciaria de Proteína , Caperuzas de ARN/metabolismo , Análisis de Secuencia de Proteína , Solanum tuberosum/metabolismo , Solanum tuberosum/virología , Tripsina/metabolismo , Proteínas del Núcleo Viral/química , Virulencia
13.
J Biol Chem ; 276(30): 27787-92, 2001 Jul 27.
Artículo en Inglés | MEDLINE | ID: mdl-11369764

RESUMEN

The virus genome-linked protein (VPg) coding region from rabbit hemorrhagic disease virus (RHDV) (isolate AST/89) was expressed in Escherichia coli by using a glutathione S-transferase-based vector. The recombinant polypeptide could be purified in good yields and was uridylylated in vitro from [alpha-32P]UTP in a reaction catalyzed by the recombinant RNA-dependent RNA polymerase from RHDV in the absence of added template RNA. The use of deletion and point mutants allowed the identification of Tyr-21 as the residue involved in uridylylation and consequently in the linkage between VPg and the viral genome. These data constitute the first report on the identity of the amino acid residue involved in VPg uridylylation in a member of the Caliciviridae family.


Asunto(s)
Virus de la Enfermedad Hemorrágica del Conejo/química , Uridina Monofosfato/metabolismo , Proteínas del Núcleo Viral/química , Secuencia de Aminoácidos , Cationes , ADN Complementario/metabolismo , ARN Polimerasas Dirigidas por ADN/metabolismo , Relación Dosis-Respuesta a Droga , Electroforesis en Gel de Poliacrilamida , Escherichia coli/metabolismo , Eliminación de Gen , Vectores Genéticos , Glutatión Transferasa/metabolismo , Virus de la Enfermedad Hemorrágica del Conejo/genética , Iones , Modelos Genéticos , Datos de Secuencia Molecular , Mutación , Plásmidos/metabolismo , Mutación Puntual , ARN Polimerasa Dependiente del ARN/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Homología de Secuencia de Aminoácido , Tirosina/metabolismo , Proteínas del Núcleo Viral/genética
14.
Virus Res ; 73(2): 103-12, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11172914

RESUMEN

Viruses of the genus Potyvirus, the largest genus of plant-infecting viruses, have a messenger-polarity ssRNA genome encapsidated by approximately 2000 units of the viral coat protein (CP), resulting in filamentous virions. Only few studies have examined potyvirus virions for the presence of other structural proteins. A protein linked covalently to the 5'-end of the genome has been identified in Tobacco vein mottling virus (TVMV) and Tobacco etch virus (TEV). In TEV, it is either the viral NIa protein or only its N-terminal domain (VPg) separated autocatalytically from the C-terminal proteinase domain (NIa-Pro). Virions of TVMV carry only the VPg. We examined virions of Potato virus A (PVA) for the genome-linked protein using immunoblotting or iodination and immunoprecipitation. The VPg ( approximately 25 kDa) only, and not the unprocessed NIa, was detected. Another signal corresponding to approximately 49 kDa was detected in disrupted, RNase-treated virions with anti-VPg antibodies but not with antibodies to NIa-Pro. Since it possibly represented a dimeric form of the VPg, self-interaction of the VPg was tested using the yeast two-hybrid system, which showed that the VPg self-interacts in the absence of viral RNA.


Asunto(s)
Potyvirus/genética , Solanum tuberosum/virología , Proteínas del Núcleo Viral/genética , Proteínas del Núcleo Viral/metabolismo , Virión/metabolismo , Immunoblotting , Potyvirus/metabolismo , Pruebas de Precipitina , Técnicas del Sistema de Dos Híbridos , Proteínas del Núcleo Viral/química
15.
Eur J Biochem ; 265(1): 336-45, 1999 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-10491190

RESUMEN

Little information is available correlating the structural properties of peptides with their immunogenicity in terms of responses via cytotoxic T lymphocytes (CTLs). The TT-NP6 chimeric peptide, consisting of two copies of a promiscuous T-helper epitope (T: residues 288-302 from the fusion protein of the measles virus) linked to the NP6 T-cytotoxic epitope (NP6: residues 52-60 from the nucleoprotein of measles virus) was able to induce virus-specific CTL responses in the absence of any adjuvant and hydrophobic component. The present work was undertaken to gain insight into structural features of the TT-NP6 peptide that may be important in optimizing the CTL immunogenicity of the peptide. Circular dichroism data, obtained in a buffer of physiological ionic strength and pH, strongly suggest a self-associated state for the peptide, which was confirmed by a sedimentation velocity experiment. However, helix association is accompanied by loss of overall helical content. Thermal-dependence studies show that the unfolding of self-associated alpha-helices is significantly more pronounced than the unfolding of isolated alpha-helices. Circular dichroism data, together with tryptic limited proteolysis, suggest the presence of a charged amino acid within the hydrophobic core. This study should provide a basis for engineering more effective immunogenic peptides against the measles virus by increasing the stability of the TT-NP6 peptide.


Asunto(s)
Epítopos/química , Virus del Sarampión/química , Proteínas Recombinantes de Fusión/química , Proteínas del Núcleo Viral/química , Proteínas Virales de Fusión/química , Secuencia de Aminoácidos , Dicroismo Circular , Calor , Espectrometría de Masas , Virus del Sarampión/inmunología , Datos de Secuencia Molecular , Proteínas de la Nucleocápside , Fragmentos de Péptidos/química , Fragmentos de Péptidos/inmunología , Fosfatos/farmacología , Desnaturalización Proteica , Estructura Secundaria de Proteína/efectos de los fármacos , Proteínas Recombinantes de Fusión/inmunología , Cloruro de Sodio/farmacología , Linfocitos T Citotóxicos/inmunología , Proteínas del Núcleo Viral/inmunología , Proteínas Virales de Fusión/inmunología
16.
Virus Genes ; 17(1): 21-4, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9778784

RESUMEN

The sequence of the 20 N-terminal amino acids of the viral protein (VPg) which is covalently attached to the genomic RNA of the bean strain of Southern bean mosaic virus (SBMV-B) has been determined. The obtained VPg sequence mapped to position 327 to 346 of the SBMV-B ORF2 product, downstream of the putative protease domain and in front of the RNA-dependent RNA polymerase. Thus indicating that the sobemovirus genomic arrangement is similar to that of subgroup II luteoviruses. Comparison with other viral sequences revealed a high similarity with the sequence of the ORF2-product of the cowpea strain of SBMV (SBMV-C). No significant similarities were detected with amino acid sequences derived of other sobemoviruses or non-related viruses.


Asunto(s)
Fabaceae/virología , Virus del Mosaico/genética , Sistemas de Lectura Abierta/genética , Plantas Medicinales , Proteínas del Núcleo Viral/genética , Secuencia de Aminoácidos , Genes Virales/genética , Genoma Viral , Datos de Secuencia Molecular , Virus del Mosaico/química , ARN Viral/genética , ARN Viral/aislamiento & purificación , Alineación de Secuencia , Análisis de Secuencia , Homología de Secuencia de Aminoácido , Proteínas del Núcleo Viral/química , Proteínas del Núcleo Viral/aislamiento & purificación , Proteínas Estructurales Virales/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA